Gossamer Bio is trading 5.04% down now at $0.16, with investor concerns focused on financing-related dilution despite broader biotechnology and major U.S. indexes moving higher on September 3, 2026.
- Its August 21 structured private placement could raise up to $250 million, but most proceeds depend on regulatory milestones.
- Coverage highlights liquidity concerns and initial warrants priced at $0.1399; no new September 3 company announcement was identified.